Jordan Gauthier, MD, MSc, is an Associate Professor at the Fred Hutchinson Cancer Center (FHCC) and the University of Washington in Seattle, WA, and the Medical Director of the FHCC Immunotherapy Long-Term-Follow-up Program. He was the first physician to be awarded the FHCC Immunotherapy Integrated Research Center Fellowship Award. An expert in the field of CAR T-cell therapy and hematopoietic cell transplantation, he has co-authored over 100 abstracts and publications in high-impact journals such as Blood, Blood Advances, The Lancet Haematology, and Nature Reviews Clinical Oncology. Dr. Gauthier was one of the first investigators to characterize the safety and efficacy of repeat CD19 CAR T-cell infusions and to investigate the concurrent use of ibrutinib with CD19 CAR T cells in patients with refractory CLL. He is the Principal Investigator of several investigator-initiated clinical trials at the FHCC aimed at preventing toxicities after CD19 CAR T-cell therapy using innovative strategies such as IL-1R blockade with anakinra, and endothelial protection with IFN-beta-1a treatment.